Compare Stocks: NRSN, GANX, CYPH, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$0.73 +6.2%	$0.73	$0.23 ▼ $3.70	$73.46M	0.09	1.41 million shs	1.12 million shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$75.07M	0.19	588,113 shs	293,835 shs
IBIO iBio	$1.40 -4.1%	$1.59	$0.56 ▼ $3.82	$72.53M	1.3	829,714 shs	304,202 shs
NRSN NeuroSense Therapeutics	$0.54 +4.2%	$0.70	$0.39 ▼ $1.98	$19.64M	1.62	317,632 shs	290,302 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	+6.23%	+21.98%	+8.59%	-30.85%	+122.80%
GANX Gain Therapeutics	+2.27%	+6.51%	-0.55%	-3.74%	+7.78%
IBIO iBio	-4.11%	+2.94%	-13.58%	-14.63%	+139,999,900.00%
NRSN NeuroSense Therapeutics	+4.21%	+12.88%	-22.16%	-38.22%	-60.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$0.73 +6.2%	$0.73	$0.23 ▼ $3.70	$73.46M	0.09	1.41 million shs	1.12 million shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$75.07M	0.19	588,113 shs	293,835 shs
IBIO iBio	$1.40 -4.1%	$1.59	$0.56 ▼ $3.82	$72.53M	1.3	829,714 shs	304,202 shs
NRSN NeuroSense Therapeutics	$0.54 +4.2%	$0.70	$0.39 ▼ $1.98	$19.64M	1.62	317,632 shs	290,302 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	+6.23%	+21.98%	+8.59%	-30.85%	+122.80%
GANX Gain Therapeutics	+2.27%	+6.51%	-0.55%	-3.74%	+7.78%
IBIO iBio	-4.11%	+2.94%	-13.58%	-14.63%	+139,999,900.00%
NRSN NeuroSense Therapeutics	+4.21%	+12.88%	-22.16%	-38.22%	-60.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYPH Cypherpunk Technologies	2.50	Moderate Buy	$0.90	22.78% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	316.67% Upside
IBIO iBio	3.13	Buy	$5.00	257.14% Upside
NRSN NeuroSense Therapeutics	2.60	Moderate Buy	$8.50	1,468.84% Upside

Current Analyst Ratings Breakdown

Latest NRSN, GANX, CYPH, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	NRSN NeuroSense Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/3/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
7/1/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$0.90
7/1/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$0.90
7/1/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
6/30/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/25/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.83 per share	N/A
GANX Gain Therapeutics	$50K	1,535.40	N/A	N/A	$0.48 per share	3.75
IBIO iBio	$400K	173.88	N/A	N/A	$0.90 per share	1.56
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYPH Cypherpunk Technologies	$4.82M	-$0.02	N/A	N/A	N/A	N/A	-48.33%	-42.21%	N/A
GANX Gain Therapeutics	-$20.16M	-$0.58	N/A	N/A	N/A	N/A	-201.44%	-136.24%	8/6/2026 (Estimated)
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)
NRSN NeuroSense Therapeutics	-$11.12M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)

Latest NRSN, GANX, CYPH, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	N/A	N/A	N/A	$0.03 million	N/A
5/14/2026	Q1 2026	CYPH Cypherpunk Technologies	-$0.0406	-$0.46	-$0.4194	-$0.46	N/A	N/A
5/12/2026	Q3 2026	IBIO iBio	-$0.06	-$0.07	-$0.01	-$0.06	$0.02 million	N/A
5/11/2026	Q1 2026	GANX Gain Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYPH Cypherpunk Technologies	N/A	27.28	27.28
GANX Gain Therapeutics	0.02	4.69	4.69
IBIO iBio	N/A	11.88	11.88
NRSN NeuroSense Therapeutics	N/A	0.31	0.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYPH Cypherpunk Technologies	30.46%
GANX Gain Therapeutics	11.97%
IBIO iBio	7.90%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
CYPH Cypherpunk Technologies	3.50%
GANX Gain Therapeutics	4.15%
IBIO iBio	2.75%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYPH Cypherpunk Technologies	40	106.46 million	102.74 million	Optionable
GANX Gain Therapeutics	20	42.65 million	40.88 million	Optionable
IBIO iBio	100	49.68 million	48.31 million	N/A
NRSN NeuroSense Therapeutics	10	37.77 million	27.42 million	Not Optionable

NRSN, GANX, CYPH, and IBIO Headlines

Recent News About These Companies

NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split

July 31, 2026 | tipranks.com

NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective

July 31, 2026 | tipranks.com

Neurosense Therapeutics is a buy, this analyst says

July 28, 2026 | cantechletter.comC

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

July 22, 2026 | prnewswire.com

Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial

July 10, 2026 | theglobeandmail.com

NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)

July 8, 2026 | nasdaq.com

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

July 6, 2026 | prnewswire.com

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

June 29, 2026 | prnewswire.com

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

June 25, 2026 | prnewswire.com

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

June 22, 2026 | prnewswire.com

NeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Purchases 250,000 Shares

June 18, 2026 | insidertrades.com

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

June 11, 2026 | prnewswire.com

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

June 9, 2026 | prnewswire.com

NRSN Share News Today

May 19, 2026 | uk.investing.com

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price

April 28, 2026 | tipranks.com

NeuroSense Announces Pricing of Insider-Led PIPE Financing

April 28, 2026 | prnewswire.com

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)

April 9, 2026 | theglobeandmail.com

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

April 6, 2026 | prnewswire.com

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

April 3, 2026 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

March 31, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, GANX, CYPH, and IBIO Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

$0.73 +0.04 (+6.23%)

As of 08/5/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Gain Therapeutics NASDAQ:GANX

$1.80 +0.04 (+2.27%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.76 -0.04 (-2.22%)

As of 08/5/2026 07:54 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

iBio NASDAQ:IBIO

$1.40 -0.06 (-4.11%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.39 -0.01 (-0.71%)

As of 04:21 AM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

NeuroSense Therapeutics NASDAQ:NRSN

$0.54 +0.02 (+4.21%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$0.52 -0.03 (-4.76%)

As of 04:00 AM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, GANX, CYPH, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, GANX, CYPH, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, GANX, CYPH, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, GANX, CYPH, and IBIO Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

NeuroSense Therapeutics NASDAQ:NRSN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, GANX, CYPH, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, GANX, CYPH, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, GANX, CYPH, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, GANX, CYPH, and IBIO Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

NeuroSense Therapeutics NASDAQ:NRSN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools